Vycor Medical Reports 31% Increase in Third-Quarter Revenue

Reuters

2025/11/15

Vycor Medical Reports 31% Increase in Third-Quarter Revenue

Vycor Medical Inc. reported revenue of $513.8 thousand for the three months ended September 30, 2025, a 31.4% increase from $390.9 thousand in the same period in 2024. The Vycor Medical division generated $492.1 thousand, up 32% year over year, primarily due to growth in the US. The NovaVision division, still in development, recorded sales of $21.7 thousand, up from $18.0 thousand in 2024. Gross profit for the quarter was $451.9 thousand with a gross margin of 88%, compared to $354.1 thousand and a 90% margin in 2024, with the margin decrease attributed to validation and shipping costs of new production runs. For the nine months ended September 30, 2025, the company reported revenue of $1.45 million, a 27.5% increase from $1.13 million in 2024. Vycor Medical division revenue rose 29.1% to $1.39 million, mainly due to international market growth. NovaVision sales were $54.1 thousand compared to $55.5 thousand in 2024. The gross profit margin for the period was 84%, down from 90% in 2024, due to higher costs and international sales mix.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vycor Medical Inc. published the original content used to generate this news brief on November 14, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2583688606"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583688606\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583688606?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-15 00:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583688606","market":"fut","top_or_hot":-1,"title":"Vycor Medical Reports 31% Increase in Third-Quarter Revenue","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vycor Medical Reports 31% Increase in Third-Quarter Revenue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vycor Medical Inc. reported revenue of $513.8 thousand for the three months ended September 30, 2025, a 31.4% increase from $390.9 thousand in the same period in 2024. The Vycor Medical division generated $492.1 thousand, up 32% year over year, primarily due to growth in the US. The NovaVision division, still in development, recorded sales of $21.7 thousand, up from $18.0 thousand in 2024. Gross profit for the quarter was $451.9 thousand with a gross margin of 88%, compared to $354.1 thousand and a 90% margin in 2024, with the margin decrease attributed to validation and shipping costs of new production runs. For the nine months ended September 30, 2025, the company reported revenue of $1.45 million, a 27.5% increase from $1.13 million in 2024. Vycor Medical division revenue rose 29.1% to $1.39 million, mainly due to international market growth. NovaVision sales were $54.1 thousand compared to $55.5 thousand in 2024. The gross profit margin for the period was 84%, down from 90% in 2024, due to higher costs and international sales mix.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vycor Medical Inc. published the original content used to generate this news brief on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vycor Medical Reports 31% Increase in Third-Quarter Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVycor Medical Reports 31% Increase in Third-Quarter Revenue\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-15 00:25</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vycor Medical Reports 31% Increase in Third-Quarter Revenue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vycor Medical Inc. reported revenue of $513.8 thousand for the three months ended September 30, 2025, a 31.4% increase from $390.9 thousand in the same period in 2024. The Vycor Medical division generated $492.1 thousand, up 32% year over year, primarily due to growth in the US. The NovaVision division, still in development, recorded sales of $21.7 thousand, up from $18.0 thousand in 2024. Gross profit for the quarter was $451.9 thousand with a gross margin of 88%, compared to $354.1 thousand and a 90% margin in 2024, with the margin decrease attributed to validation and shipping costs of new production runs. For the nine months ended September 30, 2025, the company reported revenue of $1.45 million, a 27.5% increase from $1.13 million in 2024. Vycor Medical division revenue rose 29.1% to $1.39 million, mainly due to international market growth. NovaVision sales were $54.1 thousand compared to $55.5 thousand in 2024. The gross profit margin for the period was 84%, down from 90% in 2024, due to higher costs and international sales mix.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vycor Medical Inc. published the original content used to generate this news brief on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VYCO","symbol_name":"Vycor Medical, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDLwqWyV:1","article_id":"2583688606","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583688606","pubTimestamp":1763137506,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vycor Medical Inc. reported revenue of $513.8 thousand for the three months ended September 30, 2025, a 31.4% increase from $390.9 thousand in the same period in 2024. The Vycor Medical division generated $492.1 thousand, up 32% year over year, primarily due to growth in the US. The NovaVision division, still in development, recorded sales of $21.7 thousand, up from $18.0 thousand in 2024. Gross profit for the quarter was $451.9 thousand with a gross margin of 88%, compared to $354.1 thousand and a 90% margin in 2024, with the margin decrease attributed to validation and shipping costs of new production runs. For the nine months ended September 30, 2025, the company reported revenue of $1.45 million, a 27.5% increase from $1.13 million in 2024. Vycor Medical division revenue rose 29.1% to $1.39 million, mainly due to international market growth. NovaVision sales were $54.1 thousand compared to $55.5 thousand in 2024. The gross profit margin for the period was 84%, down from 90% in 2024","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VYCO":"Vycor Medical, Inc.","BK4198":"医疗保健用品"},"translate_title":"Vycor Medical报告第三季度收入增长31%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VYCO":0.9},"content_text":"Vycor Medical Reports 31% Increase in Third-Quarter Revenue\n    \n\n        Vycor Medical Inc. reported revenue of $513.8 thousand for the three months ended September 30, 2025, a 31.4% increase from $390.9 thousand in the same period in 2024. The Vycor Medical division generated $492.1 thousand, up 32% year over year, primarily due to growth in the US. The NovaVision division, still in development, recorded sales of $21.7 thousand, up from $18.0 thousand in 2024. Gross profit for the quarter was $451.9 thousand with a gross margin of 88%, compared to $354.1 thousand and a 90% margin in 2024, with the margin decrease attributed to validation and shipping costs of new production runs. For the nine months ended September 30, 2025, the company reported revenue of $1.45 million, a 27.5% increase from $1.13 million in 2024. Vycor Medical division revenue rose 29.1% to $1.39 million, mainly due to international market growth. NovaVision sales were $54.1 thousand compared to $55.5 thousand in 2024. The gross profit margin for the period was 84%, down from 90% in 2024, due to higher costs and international sales mix.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vycor Medical Inc. published the original content used to generate this news brief on November 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}